Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Thyroid Neoplasms 1Skin Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Lung Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 12Gemcitabine 9Cetuximab 7Psychiatric Rehabilitation 6Paclitaxel 6Magnetic Resonance Spectroscopy 6Fluorouracil 6Early Intervention, Educational 6Cisplatin 6cediranib 5Leucovorin 5Carboplatin 5sargramostim 4Standard of Care 4Oxaliplatin 4Methods 4Erlotinib Hydrochloride 4Docetaxel 4Cyclophosphamide 4selpercatinib 3aldesleukin 3adagrasib 3Trastuzumab 3Therapeutics 3Pemetrexed 3Nivolumab 3Irinotecan 3Fluorodeoxyglucose F18 3Bortezomib 3Bevacizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Neoplasms × CALAA-01 × Thoracic × Clear all
NCT00689065 2013-11-01

Safety Study of CALAA-01 to Treat Solid Tumor Cancers

Calando Pharmaceuticals

Phase 1 Terminated
24 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Skin Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡